All In Biotech

Drug Trial Radar · NCT06653322

A Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

401

Actual

Start

Nov 21, 2024

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Oct 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype

Conditions

  • Asthma With Eosinophilic Phenotype

Interventions

  • HR-1703Drug

    HR-1703 will be administered by SC injection.

  • PlaceboDrug

    Matching Placebo will be administered by the SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised asthma exacerbation rate,about 48weeksTime frame: about 48weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China School of Medicine West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.